瑞舒伐他汀钙片联合阿司匹林肠溶片治疗缺血性脑血管病的价值OA

Objective To evaluate the clinical efficacy of combined administration of rosuvastatin calcium tablets and aspirin enteric-coated tablets for patients with ischemic cerebrovascular disease.Methods A total of 218 patients with ischemic cerebrovascular disease admitted to the Third Staff Hospital of Baotou Steel Group were selected and divided into the reference group(n=109)and the analysis group(n=109)using a single-blind method to receive administration of aspirin enteric-coated tablets and combined administration of aspirin enteric-coated tablets and rosuvastatin,respectively,and the clinical efficacy was compared between the two groups.The study lasted from January 2021 to December 2022.Results The blood liquid level in the analysis group were better than those in the reference group,with a statistically significant difference(P<0.05).The activities of the national institute of health stroke scale(NIHSS)score,Barthel index,the MOS item short form health survey(SF-36)score,and treatment total effectiveness rate of the analysis group were higher than those of the reference group,with statistically significant differences(P<0.05).Conclusion For patients with ischemic cerebrovascular disease,the combined administration of rosuvastatin calcium tablets and aspirin enteric-coated tablets has a definite overall treatment effect,can effectively improve the patient's blood lipid levels,reduce the degree of neurological deficits,improve daily living activities and quality of life,and is worth promoting in the clinic.